Editas Medicine names Charles Albright as chief scientific officer
Dr. Albright brings to Editas more than 25 years of life sciences industry and academic leadership experience, most recently serving as Vice President of Genetically Defined Diseases and Genomics at Bristol-Myers Squibb (BMS).
Over his career, Dr. Albright has led discovery programs that advanced investigational medicines into clinical development in a wide range of therapeutic areas, including neurodegeneration, pain, psychiatry, oncology and inflammation.
Prior to his position as Vice President of Genetically Defined Diseases and Genomics, Dr. Albright held multiple scientific leadership roles in Neuroscience Biology at BMS.
Previously, he held positions at Incyte Corporation and DuPont Pharmaceuticals and was an Assistant Professor of Biochemistry at Vanderbilt University.
Dr. Albright received a Bachelor of Science in Chemical Engineering and a Ph.D. in Biology from the Massachusetts Institute of Technology (MIT). He was a postdoctoral fellow in the laboratory of Professor Robert Weinberg at the Whitehead Institute for Biomedical Research at MIT. ■
LATEST MOVES FROM Massachusetts
- Haemonetics Corporation appoints Robert E. Abernathy to board
- Tetraphase Pharma appoints Kamalam Unninayar as CFO
- Boston Biomedical appoints Edgar Braendle as vice president
- Analogic Corporation appoints Joseph Whitters to board
- Eleven Biotherapeutics appoints Richard F. Fitzgerald as interim CFO
More inside POST
Grubhub completes acquisition of Eat24 Companies